The University of Michigan Cancer Center
Welcome,         Profile    Billing    Logout  
 12 Trials 
43 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Yanik, Gregory
NCT05457556: Mismatched Related Donor Versus Matched Unrelated Donor Stem Cell Transplantation for Children, Adolescents, and Young Adults With Acute Leukemia or Myelodysplastic Syndrome

Recruiting
3
435
Canada, US, RoW
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Marrow Aspiration, Busulfan, 1, 4-Bis[methanesulfonoxy]butane, BUS, Busilvex, Bussulfam, Busulfanum, Busulfex, Busulphan, CB 2041, CB-2041, Glyzophrol, GT 41, GT-41, Joacamine, Methanesulfonic Acid Tetramethylene Ester, Methanesulfonic acid, tetramethylene ester, Mielucin, Misulban, Misulfan, Mitosan, Myeleukon, Myeloleukon, Myelosan, Mylecytan, Myleran, Sulfabutin, Tetramethylene Bis(methanesulfonate), Tetramethylene bis[methanesulfonate], WR-19508, Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Asta B 518, B 518, B-518, B518, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR 138719, WR- 138719, WR-138719, WR138719, Echocardiography, EC, Fludarabine, Fluradosa, Haploidentical Hematopoietic Cell Transplantation, Haploidentical Stem Cell Transplantation, HLA-Haploidentical Hematopoietic Cell Transplantation, Stem Cell Transplantation, Haploidentical, Lapine T-Lymphocyte Immune Globulin, Anti-Thymocyte Globulin Rabbit, Antithymocyte Globulin Rabbit, Antithymocyte globulin rabbit ATG, Grafalon, Imtix, Rabbit Anti-Human Thymocyte Globulin (RATG), Rabbit Anti-Thymocyte Globulin, Rabbit Antithymocyte Globulin, Rabbit ATG, Thymoglobulin, Lumbar Puncture, LP, Spinal Tap, Matched Unrelated Donor Hematopoietic Cell Transplantation, MUD-HCT, Melphalan, Alanine Nitrogen Mustard, CB-3025, L-PAM, L-Phenylalanine Mustard, L-Sarcolysin, L-Sarcolysin Phenylalanine mustard, L-Sarcolysine, Melphalan for Injection-Hepatic Delivery System, Melphalanum, Phenylalanine Mustard, Phenylalanine Nitrogen Mustard, Sarcoclorin, Sarkolysin, WR-19813, Methotrexate, Abitrexate, Alpha-Methopterin, Amethopterin, Brimexate, CL 14377, CL-14377, Emtexate, Emthexat, Emthexate, Farmitrexat, Fauldexato, Folex, Folex PFS, Lantarel, Ledertrexate, Lumexon, Maxtrex, Medsatrexate, Metex, Methoblastin, Methotrexate LPF, Methotrexate Methylaminopterin, Methotrexatum, Metotrexato, Metrotex, Mexate, Mexate-AQ, MTX, Novatrex, Rheumatrex, Texate, Tremetex, Trexeron, Trixilem, WR-19039, Multigated Acquisition Scan, Blood Pool Scan, Equilibrium Radionuclide Angiography, Gated Blood Pool Imaging, Gated Heart Pool Scan, MUGA, MUGA Scan, Multi-Gated Acquisition Scan, Radionuclide Ventriculogram Scan, Radionuclide Ventriculography, RNVG, SYMA Scanning, Synchronized Multigated Acquisition Scanning, Mycophenolate Mofetil, CellCept, MMF, Myeloablative Conditioning, Myeloablation, Myeloablative, Myeloablative Cytoreduction, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration, Rituximab, ABP 798, BI 695500, BI-695500, BI695500, Blitzima, C2B8 Monoclonal Antibody, Chimeric Anti-CD20 Antibody, CT-P10, IDEC 102, IDEC-102, IDEC-C2B8, IDEC-C2B8 Monoclonal Antibody, IDEC102, Ikgdar, Mabtas, MabThera, Monoclonal Antibody IDEC-C2B8, PF 05280586, PF-05280586, PF05280586, Riabni, Ritemvia, Rituxan, Rituximab ABBS, Rituximab ARRX, Rituximab Biosimilar ABP 798, Rituximab Biosimilar BI 695500, Rituximab Biosimilar CT-P10, Rituximab Biosimilar GB241, Rituximab Biosimilar IBI301, Rituximab Biosimilar JHL1101, Rituximab Biosimilar PF-05280586, Rituximab Biosimilar RTXM83, Rituximab Biosimilar SAIT101, Rituximab Biosimilar SIBP-02, rituximab biosimilar TQB2303, Rituximab PVVR, Rituximab-abbs, Rituximab-arrx, Rituximab-blit, Rituximab-pvvr, Rituximab-rite, Rituximab-rixa, Rituximab-rixi, Rixathon, Riximyo, RTXM 83, RTXM-83, RTXM83, Ruxience, Truxima, T-Cell Depletion Therapy, T-Cell Depletion, T-Lymphocyte Depletion Therapy, Tacrolimus, FK 506, FK-506, FK506, Fujimycin, Hecoria, Prograf, Protopic, Tacforius, Thiotepa, 1,1',1''-Phosphinothioylidynetrisaziridine, Girostan, N,N', N''-Triethylenethiophosphoramide, Oncotiotepa, SH 105, SH-105, SH105, STEPA, Tepadina, Tepylute, TESPA, Tespamin, Tespamine, Thio-Tepa, Thiofosfamide, Thiofozil, Thiophosphamide, Thiophosphoamide, Thiophosphoramide, Thiotef, Tifosyl, TIO TEF, Tio-tef, Triethylene Thiophosphoramide, Triethylenethiophosphoramide, Tris(1-aziridinyl)phosphine sulfide, TSPA, WR 45312, Total-Body Irradiation, SCT_TBI, TBI, Total Body Irradiation, Whole Body, Whole Body Irradiation, Whole-Body Irradiation
Children's Oncology Group
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Mixed Phenotype Acute Leukemia, Myelodysplastic Syndrome
12/27
12/27
PAVO, NCT02445222 / 2014-001673-14: CAR-T Long Term Follow Up (LTFU) Study

Recruiting
3
1400
Europe, Canada, Japan, US, RoW
Previously treated CAR-T patients
Novartis Pharmaceuticals, University of Pennsylvania
Long Term Safety of Patients Receiving CAR-T in an Eligible Clinical Trial or Managed Access Program
02/36
02/36
NCT05922761: BElumosudil for Bronchiolitis Obliterans Prevention/Therapy (BEBOP)

Recruiting
2
45
US
Belumosudil, Rezurock, KD025, 2-{3-[4-(1H-indazol-5-ylamino)-2-quinazolinyl]phenoxy}-N-(propan-2-yl) acetamide, C26H24N6O2, Fluticasone, Fluticasone Propionate, Azithromycin, Zithromax, Prednisone, Montelukast, Singulair
Dana-Farber Cancer Institute, Sanofi, National Heart, Lung, and Blood Institute (NHLBI)
Bronchiolitis Obliterans Syndrome, Bronchiolitis Obliterans, Lung Diseases, Chronic Graft Versus Host Disease
06/26
12/26
VBP301, NCT05984199: Donor-Derived Anti-CD33 CAR T Cell Therapy (VCAR33) in Patients With Relapsed or Refractory AML After Allogeneic Hematopoietic Cell Transplant

Recruiting
1/2
24
US
VCAR33
Vor Biopharma
Leukemia, Myeloid, Acute
12/24
11/26
NCT01590680: Expanded Access Protocol Using 131I-MIBG

Available
N/A
US
I-131 MIBG, I-131 Iobenguane, I-131 meta-iodobenzylguanidine
Jubilant DraxImage Inc.
Neuroblastoma, Pheochromocytoma, Paraganglioma
 
 
NCT03601442: CTL019 Out of Specification MAP for ALL or DLBCL Patients

Available
N/A
Canada, US, RoW
CTL019, tisagenlecleucel, Kymriah
Novartis Pharmaceuticals
Acute Lymphoblastic Leukemia (ALL), Diffuse Large B-cell Lymphoma (DLBCL)
 
 
NCT05866302: Parametric Response Mapping (PRM) for the Detection of Chronic Lung Injury in Hematopoietic Cell Transplant Recipients

Recruiting
N/A
375
US
University of Michigan Rogel Cancer Center, National Heart, Lung, and Blood Institute (NHLBI)
Chronic Lung Disease, Hematopoietic Cell Transplantation, Graft Versus Host Disease
05/28
05/28
NCT01351545: A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)

Recruiting
N/A
99999
US
A multicenter access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs)
Center for International Blood and Marrow Transplant Research, National Marrow Donor Program
Hematologic Malignancies, Inherited Disorders of Metabolism, Inherited Abnormalities of Platelets, Histiocytic Disorders, Acute Myelogenous Leukemia (AML or ANLL), Acute Lymphoblastic Leukemia (ALL), Other Acute Leukemia, Chronic Myelogenous Leukemia (CML), Myelodysplastic (MDS) / Myeloproliferative (MPN) Diseases, Other Leukemia, Hodgkin Lymphoma, Non-hodgkin Lymphoma, Multiple Myeloma/ Plasma Cell Disorder (PCD), Inherited Abnormalities of Erythrocyte Differentiation or Function, Disorders of the Immune System, Autoimmune Diseases, Severe Aplastic Anemia
10/41
10/41
Williams, Kirsten
NCT03842696: Vorinostat for Graft vs Host Disease Prevention in Children, Adolescents and Young Adults Undergoing Allogeneic Blood and Marrow Transplantation

Recruiting
1/2
49
US
Vorinostat, Blood and Marrow Transplant (BMT), Tacrolimus (or cyclosporine), Methotrexate, Mycophenolate Mofetil (MMF), Cyclophosphamide
University of Michigan Rogel Cancer Center, National Institutes of Health (NIH), National Center for Advancing Translational Sciences (NCATS)
Hematologic Diseases, Acute Leukemia in Remission, Chronic Myelogenous Leukemia - Chronic Phase, Chronic Myelogenous Leukemia, Accelerated Phase, Chronic Myelogenous Leukemia, Blastic Phase, Myelodysplastic Syndromes, Mantle Cell Lymphoma, Follicular Lymphoma, Diffuse Large B Cell Lymphoma, Non Hodgkin Lymphoma, Graft Vs Host Disease, Graft-versus-host-disease
06/25
06/26
REALIZE, NCT03633955: Pilot Imaging Study of Leukemia

Recruiting
1
60
US
FLT
University of Oklahoma, Emory University
Acute Lymphocytic Leukemia, Acute Myeloid Leukemia, Ambiguous Lineage Leukemia or Lymphoma, Myeloma
03/25
04/27
OU-SCC-REVEAL, NCT03541889: REVEAL Biomarkers of Engraftment After Alternative Donor HSCT

Recruiting
1
50
US
FLT imaging and TK1 blood measurements
University of Oklahoma, Emory University, University of Michigan, University Hospitals Cleveland Medical Center
Primary Graft Failure
05/25
05/26
NCT05866302: Parametric Response Mapping (PRM) for the Detection of Chronic Lung Injury in Hematopoietic Cell Transplant Recipients

Recruiting
N/A
375
US
University of Michigan Rogel Cancer Center, National Heart, Lung, and Blood Institute (NHLBI)
Chronic Lung Disease, Hematopoietic Cell Transplantation, Graft Versus Host Disease
05/28
05/28
AnswerLine, Cancer
NCT04754399: Cannabidiol (CBD) for Treatment of Aromatase Inhibitor-Associated Arthralgias

Completed
2
40
US
Cannabidiol (CBD), Epidiolex
University of Michigan Rogel Cancer Center, American Society of Clinical Oncology
Arthralgia, Breast Cancer
10/23
10/23
VEnT, NCT06617455: Fezolinetant for the Improvement of Vasomotor Symptoms in Breast Cancer Patients Taking Endocrine Therapy, VENT Trial

Not yet recruiting
2
36
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Fezolinetant, Placebo Administration, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration
University of Michigan Rogel Cancer Center, The Breast Cancer Research Foundation
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Breast Ductal Carcinoma In Situ, Localized Breast Carcinoma
09/26
12/26
CuSToMIze, NCT05894083: A Phase II Study for p16+ Oropharyngeal Cancer PerSonalized De-escalation Treatment at University of MIchigan

Recruiting
2
150
US
Surgery, Chemoradiation, Observation, Post-operative radiation
University of Michigan Rogel Cancer Center
Oropharyngeal Cancer, Squamous Cell Carcinoma of the Oropharynx
04/25
04/29
FAALCON, NCT04748042: Focal Radiation With Pulsed Systemic Therapy of Abiraterone, Androgen Deprivation Therapy (ADT), Lynparza Towards Castration Sensitive Oligometastatic Prostate Cancer

Recruiting
2
29
US
Abiraterone, Zytiga, Prednisone, External Beam Radiotherapy, Androgen Deprivation Therapy (ADT), Olaparib, Lynparza, AZD2281
University of Michigan Rogel Cancer Center
Prostate Cancer, Castrate Sensitive Prostate Cancer, Oligometastatic Disease
05/25
05/25
NCT04845035: Pediatric-Inspired Chemotherapy Plus Tyrosine Kinase Inhibitor in Adult Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Withdrawn
2
23
US
Dasatinib, Ponatinib, Berlin-Frankfurt-Münster Chemotherapy, Methotrexate and Cytarabine
University of Michigan Rogel Cancer Center, Takeda
Acute Lymphoblastic Leukemia
01/26
01/29
NCT04858256: Pacritinib in Relapsed/Refractory T-cell Lymphoproliferative Neoplasms

Recruiting
2
100
US
Pacritinib
University of Michigan Rogel Cancer Center, National Institutes of Health (NIH), National Cancer Institute (NCI)
T-Cell Neoplasm, Lymphoproliferative Disorders
11/27
11/28
AVB500-PC-005, NCT04983407: Safety and Efficacy Study of AVB-S6-500 (Batiraxcept) in Patients With Advanced Pancreatic Adenocarcinoma

Terminated
1b/2
34
US
batiraxcept, AVB-S6-500, Nab paclitaxel, Abraxane, Gemcitabine
Aravive, Inc.
Pancreatic Adenocarcinoma
08/23
08/23
NCT03520075 / 2018-004568-72: Study of ASTX029 in Subjects With Advanced Solid Tumors

Active, not recruiting
1/2
190
Europe, US
ASTX029
Taiho Oncology, Inc.
Solid Tumor, Adult
08/24
12/25
BilT-04, NCT04203160: Gemcitabine and Cisplatin With or Without CPI-613 as First Line Therapy for Patients With Advanced Unresectable Biliary Tract Cancer

Completed
1/2
75
US
CPI 613, Devimistat®, Gemcitabine, Gemzar®, Cisplatin, CDDP, Platinol®, NSC-119875
University of Michigan Rogel Cancer Center
Biliary Tract Cancer
04/24
04/24
NCT03559049: Rucaparib and Pembrolizumab for Maintenance Therapy in Stage IV Non-Squamous Non-Small Cell Lung Cancer

Active, not recruiting
1/2
25
US
Pembrolizumab, Pemetrexed, Carboplatin, Rucaparib
University of Michigan Rogel Cancer Center, Merck Sharp & Dohme LLC, Clovis Oncology, Inc.
Stage IV Non-small Cell Lung Cancer
01/25
01/28
CAPS, NCT03781986: APG-115 in Salivary Gland Cancer Trial

Active, not recruiting
1/2
41
US
APG-115, Carboplatin
University of Michigan Rogel Cancer Center, Ascentage Pharma Group Inc.
Malignant Salivary Gland Cancer, Salivary Gland Cancer
06/25
12/25
NCT06616155: Ruxolitinib and Enzalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer

Not yet recruiting
1/2
39
US
Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Scan, Bone Scintigraphy, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Enzalutamide, ASP9785, MDV 3100, MDV-3100, MDV3100, Xtandi, Ruxolitinib, INCB 018424, INCB-018424, INCB-18424, INCB18424, Oral JAK Inhibitor INCB18424
University of Michigan Rogel Cancer Center, Incyte Corporation
Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8
03/27
03/29
NCT05902988: A Phase I/II Study of VLS-1488 in Subjects with Advanced Cancer

Recruiting
1/2
120
US
VLS-1488
Volastra Therapeutics, Inc.
Advanced Solid Tumor, High Grade Serous Adenocarcinoma of Ovary, Squamous Non-small-cell Lung Cancer, Triple Negative Breast Cancer, Gastric Adenocarcinoma, Colorectal Adenocarcinoma, Esophageal Squamous Cell Carcinoma, Esophageal Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Transitional Cell Carcinoma of Bladder, Head and Neck Squamous Cell Carcinoma, Ovarian Carcinosarcoma, Uterine Carcinosarcoma, Uterine Serous Carcinoma, Endometrium Cancer, Chromosomal Instability
12/25
06/26
LiFFT, NCT05918640: Lurbinectedin in FET-Fused Tumors

Recruiting
1/2
56
US
Lurbinectedin
Children's Hospital of Philadelphia, Jazz Pharmaceuticals, Stand Up To Cancer
Ewing Sarcoma, Desmoplastic Small Round Cell Tumor, Pediatric Cancer, Undifferentiated Sarcoma
07/26
07/28
ASCLEPIuS, NCT04194554: A Multi-Center Trial of Androgen Suppression With Abiraterone Acetate, Leuprolide, PARP Inhibition and Stereotactic Body Radiotherapy in Prostate Cancer

Active, not recruiting
1/2
102
US
Niraparib, Leuprolide, Abiraterone Acetate, Stereotactic body radiotherapy (SBRT), Ultra-hypofractionated radiotherapy
University of Michigan Rogel Cancer Center, Janssen Scientific Affairs, LLC
Prostate Cancer
11/26
05/27
NCT04703920: Talazoparib in Combination With Belinostat for Metastatic Breast Cancer, Metastatic Castration Resistant Prostate Cancer, and Metastatic Ovarian Cancer

Active, not recruiting
1
26
US
Talazoparib, Belinostat
University of Michigan Rogel Cancer Center, Pfizer, Acrotech Biopharma Inc.
Metastatic Breast Cancer, Metastatic Castration-resistant Prostate Cancer, Metastatic Ovarian Carcinoma
12/24
12/24
NCT04477200: Mycophenolate Mofetil Combined With Radiation Therapy in Glioblastoma

Recruiting
1
68
US
Mycophenolate Mofetil, MMF, Radiation Therapy, RT, Re-resection (as part of standard of care), Temozolomide, TMZ
University of Michigan Rogel Cancer Center, National Cancer Institute (NCI)
Recurrent Glioblastoma, Recurrent Gliosarcoma, Recurrent Astrocytoma, Grade IV, Newly Diagnosed Glioblastoma, Newly Diagnosed Gliosarcoma, Newly Diagnosed Astrocytoma, Grade IV
10/25
10/27
NCT04852471: Improving Quality of Life Using Patient Reported Outcomes Measures Post-operative Via Text Messaging

Completed
N/A
102
US
Standard Post-Operative Counseling + FACT-G, PROM symptom tracker
University of Michigan Rogel Cancer Center
Gynecologic Cancer
05/23
05/23
NCT05140252: Avoiding Low-value Treatments in Older Women With Early-stage Breast Cancer: Piloting a Patient Decision Aid

Completed
N/A
22
US
Breast cancer decision aid
University of Michigan Rogel Cancer Center
Breast Cancer
09/23
09/23
NCT05704790: Feasibility and Acceptability of Brief, Telehealth Cognitive Compensatory Training for Pediatric Cancer Patients

Completed
N/A
26
US
Cognitive Compensatory Training
University of Michigan Rogel Cancer Center
Pediatric Cancer
07/24
07/24
NCT05764005: Optimizing Active Surveillance in Low-Risk Prostate Cancer: a Pilot Study

Completed
N/A
40
US
web-based tool (MAP- Management of Active surveillance in Prostate Cancer), MUSIC website
University of Michigan Rogel Cancer Center, National Cancer Institute (NCI)
Prostate Cancer
03/24
03/24
NCT05583422: Evaluating a Pharmacogenetic Testing Panel in Patients Suspected to be at Increased Risk for Pharmacogenetics-related AEs While Receiving Fluoropyrimidine or Irinotecan Therapy

Active, not recruiting
N/A
16
US
DPYD or UGT1A1 variants
University of Michigan Rogel Cancer Center
Cancer
12/25
12/25
NCT05965180: Interstitial Assessment of Architectural Heterogeneity in Prostate Cancer Using a Fine Needle Photoacoustic Probe

Recruiting
N/A
20
US
Fine Needle Photoacoustic Probe
University of Michigan Rogel Cancer Center, National Cancer Institute (NCI)
Prostate Cancer
10/25
10/25
MiGHT, NCT05162846: Methods for Increasing Genetic Testing Uptake in Michigan

Active, not recruiting
N/A
831
US
Publicly available genetic testing resources, Virtual genetics navigator, Motivational interviewing (MI)
University of Michigan Rogel Cancer Center, National Cancer Institute (NCI)
Breast Cancer, Colorectal Cancer, Ovarian Cancer, Prostate Cancer, Pancreatic Cancer, Endometrial Cancer, History of Cancer
12/26
12/26
NCT05578898: CLEAR Care Companion Application

Completed
N/A
28
US
CLEAR Care Companion (CC) application
University of Michigan Rogel Cancer Center
Bladder Cancer, Radical Cystectomy
07/24
07/24
B-REP, NCT06100263: Breast Cancer Resiliency Through Exercise Program

Recruiting
N/A
200
US
Individualized exercise program, Control Arm
University of Michigan Rogel Cancer Center
Breast Cancer Female
12/26
12/26
NCT05945121: Prehabilitation Program to Improve Cardiac Reserve in High-Risk Patients Undergoing Hematopoietic Stem Cell Transplantation

Recruiting
N/A
10
US
Cardio-oncology program
University of Michigan Rogel Cancer Center, National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI)
Hematopoietic Stem Cell Transplant
08/27
08/27
NCT00843375: Evaluation of Stool Based Markers for the Early Detection of Colorectal Cancers and Adenomas

Recruiting
N/A
1200
Canada, US, RoW
University of Michigan Rogel Cancer Center, Early Detection Research Network, Clinical Genomics Pathology, VolitionRx, Department of Health and Human Services, Great Lakes New England Clinical Validation Center, National Cancer Institute (NCI)
Colonic Neoplasms
03/28
03/28
NCT05866302: Parametric Response Mapping (PRM) for the Detection of Chronic Lung Injury in Hematopoietic Cell Transplant Recipients

Recruiting
N/A
375
US
University of Michigan Rogel Cancer Center, National Heart, Lung, and Blood Institute (NHLBI)
Chronic Lung Disease, Hematopoietic Cell Transplantation, Graft Versus Host Disease
05/28
05/28
Pitt, Susan
NCT06073223: Intervention to Decrease Overtreatment of Patients With Low-risk Thyroid Cancer

Recruiting
N/A
70
US
Usual Care, CQUPLE
University of Michigan Rogel Cancer Center, National Cancer Institute (NCI)
Thyroid Cancer
04/25
04/25
Jensen, Katy
NCT06073223: Intervention to Decrease Overtreatment of Patients With Low-risk Thyroid Cancer

Recruiting
N/A
70
US
Usual Care, CQUPLE
University of Michigan Rogel Cancer Center, National Cancer Institute (NCI)
Thyroid Cancer
04/25
04/25

Download Options